Purdue Pharma L.P. to Present Data Examining the Inverse Association Between Overdose Risk and Age at International Conference on Opioids

Published: Jun 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STAMFORD, Conn., June 7, 2013 – Purdue Pharma L.P. will present a data analysis that examined the risk for opioid overdose categorized by opioid dose and age to understand age-dose differences in the risk of opioid overdose and explore potential confounding by abuse. The findings will be shared at the International Conference on Opioids in Boston, June 9-11, 2013.

The data will be presented during the following times at ICOO:

-- Poster #16 – Sunday, June 9

     -- 10:10 – 10:40 a.m.

     -- 12:40 – 2:10 p.m.

     -- 3:55 – 4:25 p.m.

“The Association Between Prescribed Opioid Dose and Risk of Overdose Events by Age and Potential Confounding by Abuse.”

A. DeVeaugh-Geiss, A. Kadakia, H. Chilcoat, P. Coplan

An analysis of an insurance claims database was conducted covering the period between January 2008 and March 2012, in which approximately 10.8 million people were dispensed a new opioid prescription. There were 3,688 cases of opioid overdose recorded in the database among those users of opioids.

These results were taken from ongoing analyses of the MarketScan dataset among adults between 18 and 64 years of age (Commercial) and 65 years of age or older (Medicare) with a new opioid prescription. Daily opioid exposure and person-years for all patients were categorized using 10 morphine-equivalent dose categories that ranged from 0 mg to 350 mg per day or greater.

Although recent studies have reported an association between a higher risk for opioid overdose and higher doses of prescribed opioids, the impact of age on the association between overdose and opioid dose that, to our knowledge, has not been explored. Furthermore, the impact of other factors such as opioid type and concomitant sedative/hypnotic use on the association between overdose risk and prescribed opioid dose was analyzed. While these analyses do not control for all possible factors associated with overdose, these stratified analyses are relevant to clinical decision making, in which patient characteristics guide treatment decisions.

The research was funded by Purdue Pharma L.P., and all four study authors are full-time employees of the Company.

About Purdue Pharma L.P.

Purdue Pharma L.P. and its associated U.S. companies are privately held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue Pharma is engaged in the research, development, production and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.


Libby Holman

Associate Director

Public Affairs

Tel: 203-588-7670

Cell: 203-609-1291

Email: libby.holman@pharma.com

Help employers find you! Check out all the jobs and post your resume.

Back to news